FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283700944> ?p ?o ?g. }

• W4283700944 endingPage "600" @default.
• W4283700944 startingPage "600.1" @default.
• W4283700944 abstract "Background Recently, it has been recognized that frailty and pre-frailty are common in patients with rheumatoid arthritis (RA) [1]. Whether frailty status portends an increased risk of adverse outcomes in patients with RA on biologic or targeted synthetic disease modifying anti-rheumatic drugs (b- or tsDMARDs) remains unknown. Objectives To evaluate the association between frailty and adverse outcomes in patients with RA exposed to b- or tsDMARDs. Methods Using the IBM/Watson MarketScan Commercial Claims and Encounters Databases, we identified all patients with RA who filled new prescriptions (or received infusions) for TNFα antagonists (TNFi), non-TNFi biologics (rituximab, abatacept, tocilizumab) or Janus Kinase inhibitors (JAKi) between 2008-2019. We used a 1-year lookback period without the use of these drugs to identify new users. The date of the first prescription within these three drug categories was the index date. Patients’ frailty risk score was calculated using the Claims-Based Frailty Index (CFI) [2], which estimates a deficit-accumulation frailty index using International Classification of Diseases codes, Current Procedural Terminology codes, and Healthcare Common Procedure Coding System codes in administrative claims data in the 1-year baseline period. The index ranges from 0 (not at all frail) to 1 (severely frail). The primary outcome was time to serious infections (those requiring hospitalization); secondary outcomes: any infection (outpatient or inpatient encounters) and all-cause hospitalizations. Patients were followed until 1) outcome occurrence; 2) disenrollment; 3) >90 days elapsed (or >180 days for rituximab) without further fills of the first drug categories; 4) they filled/received infusions of b-/tsDMARDs from a different drug category; or 5) 2 years after index. Cox proportional hazards adjusting for demographics, calendar year, serious and/or opportunistic infections in the 12-months prior to index were used to estimate the adjusted hazard ratios (aHR) and 95% confidence intervals (CIs) for each outcome. In separate model, we additionally adjusted for comorbidity burden, and health care utilization (HCU). Results A total of 62,246 patients with RA met our inclusion criteria of whom 50,910 (82%) started TNFi as their first biologic, 9525 (15%) non-TNFi biologics, and 1811 (3%) JAKi. Among these, 3928 (6%) were considered frail. In multivariable analyses, frail patients had higher risk of serious infections compared to non-frail patients (aHR 2.37, 95% CI 2.05-2.74) which decreased to aHR 1.34, 95% CI 1.13-1.58 (Table 1) after adjusting for comorbidity burden and the HCU. Similarly, frailty was associated with increased risk of any infection (aHR 1.18, 95% CI 1.11-1.25), and all-cause hospitalizations (aHR 1.34, 95% CI 1.21-1.49) relative to non-frail individuals. Table 1. Multivariable models evaluating the association between frailty status and inpatient infections as the outcome Variable #Hazard Ratio (95% Confidence Interval) @Hazard Ratio (95% Confidence Interval) Frail 2.37 (2.05, 2.74 ) 1.34 (1.13, 1.58 ) #Model adjusts for age, sex, major infection requiring inpatient admission in 12 months prior, concomitant baseline drugs such as csDMARDs, glucocorticoids, NSAIDs and opioids @Model additionally adjusts for Chalrson comorbidy score and healthcare utilization Conclusion Frailty is an important predictor for the risk of adverse outcomes among patients with RA treated with b- or tsDMARDs. Our findings underscore the need for considering this parameter in patient evaluations (even among younger patients) in the clinic. References [1]Salaffi F et al: Prevalence of frailty and its associated factors in patients with rheumatoid arthritis: a cross-sectional analysis . Clin Rheumatol 2019 [2]Kim DH et al. Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study . J Gerontol A Biol Sci Med Sci 2019 Acknowledgements I have no acknowledgements to declare. Disclosure of Interests None declared" @default.
• W4283700944 created "2022-06-30" @default.
• W4283700944 creator A5004282984 @default.
• W4283700944 creator A5005249341 @default.
• W4283700944 creator A5013326966 @default.
• W4283700944 creator A5020280775 @default.
• W4283700944 creator A5025292802 @default.
• W4283700944 creator A5036393284 @default.
• W4283700944 creator A5045447914 @default.
• W4283700944 creator A5050657754 @default.
• W4283700944 creator A5060287466 @default.
• W4283700944 creator A5070342360 @default.
• W4283700944 creator A5086957128 @default.
• W4283700944 creator A5088568718 @default.
• W4283700944 creator A5089184217 @default.
• W4283700944 date "2022-05-23" @default.
• W4283700944 modified "2023-09-26" @default.
• W4283700944 title "POS0656 FRAILTY AND RISK OF ADVERSE OUTCOMES IN BIOLOGIC OR TARGETED-SYNTHETIC DMARD TREATED PATIENTS WITH RHEUMATOID ARTHRITIS" @default.
• W4283700944 doi "https://doi.org/10.1136/annrheumdis-2022-eular.3939" @default.
• W4283700944 hasPublicationYear "2022" @default.
• W4283700944 type Work @default.
• W4283700944 citedByCount "0" @default.
• W4283700944 crossrefType "journal-article" @default.
• W4283700944 hasAuthorship W4283700944A5004282984 @default.
• W4283700944 hasAuthorship W4283700944A5005249341 @default.
• W4283700944 hasAuthorship W4283700944A5013326966 @default.
• W4283700944 hasAuthorship W4283700944A5020280775 @default.
• W4283700944 hasAuthorship W4283700944A5025292802 @default.
• W4283700944 hasAuthorship W4283700944A5036393284 @default.
• W4283700944 hasAuthorship W4283700944A5045447914 @default.
• W4283700944 hasAuthorship W4283700944A5050657754 @default.
• W4283700944 hasAuthorship W4283700944A5060287466 @default.
• W4283700944 hasAuthorship W4283700944A5070342360 @default.
• W4283700944 hasAuthorship W4283700944A5086957128 @default.
• W4283700944 hasAuthorship W4283700944A5088568718 @default.
• W4283700944 hasAuthorship W4283700944A5089184217 @default.
• W4283700944 hasBestOaLocation W42837009441 @default.
• W4283700944 hasConcept C126322002 @default.
• W4283700944 hasConcept C141071460 @default.
• W4283700944 hasConcept C197934379 @default.
• W4283700944 hasConcept C2426938 @default.
• W4283700944 hasConcept C2776233030 @default.
• W4283700944 hasConcept C2777178219 @default.
• W4283700944 hasConcept C2777575956 @default.
• W4283700944 hasConcept C2778886723 @default.
• W4283700944 hasConcept C2779338263 @default.
• W4283700944 hasConcept C2779513377 @default.
• W4283700944 hasConcept C2779605438 @default.
• W4283700944 hasConcept C2780653079 @default.
• W4283700944 hasConcept C2908647359 @default.
• W4283700944 hasConcept C45827449 @default.
• W4283700944 hasConcept C71924100 @default.
• W4283700944 hasConcept C98274493 @default.
• W4283700944 hasConcept C99454951 @default.
• W4283700944 hasConceptScore W4283700944C126322002 @default.
• W4283700944 hasConceptScore W4283700944C141071460 @default.
• W4283700944 hasConceptScore W4283700944C197934379 @default.
• W4283700944 hasConceptScore W4283700944C2426938 @default.
• W4283700944 hasConceptScore W4283700944C2776233030 @default.
• W4283700944 hasConceptScore W4283700944C2777178219 @default.
• W4283700944 hasConceptScore W4283700944C2777575956 @default.
• W4283700944 hasConceptScore W4283700944C2778886723 @default.
• W4283700944 hasConceptScore W4283700944C2779338263 @default.
• W4283700944 hasConceptScore W4283700944C2779513377 @default.
• W4283700944 hasConceptScore W4283700944C2779605438 @default.
• W4283700944 hasConceptScore W4283700944C2780653079 @default.
• W4283700944 hasConceptScore W4283700944C2908647359 @default.
• W4283700944 hasConceptScore W4283700944C45827449 @default.
• W4283700944 hasConceptScore W4283700944C71924100 @default.
• W4283700944 hasConceptScore W4283700944C98274493 @default.
• W4283700944 hasConceptScore W4283700944C99454951 @default.
• W4283700944 hasIssue "Suppl 1" @default.
• W4283700944 hasLocation W42837009441 @default.
• W4283700944 hasOpenAccess W4283700944 @default.
• W4283700944 hasPrimaryLocation W42837009441 @default.
• W4283700944 hasRelatedWork W2211552606 @default.
• W4283700944 hasRelatedWork W2404059674 @default.
• W4283700944 hasRelatedWork W2901546121 @default.
• W4283700944 hasRelatedWork W2902184252 @default.
• W4283700944 hasRelatedWork W2949158528 @default.
• W4283700944 hasRelatedWork W3160874207 @default.
• W4283700944 hasRelatedWork W4283653027 @default.
• W4283700944 hasRelatedWork W4283700944 @default.
• W4283700944 hasRelatedWork W4310797979 @default.
• W4283700944 hasRelatedWork W2341212936 @default.
• W4283700944 hasVolume "81" @default.
• W4283700944 isParatext "false" @default.
• W4283700944 isRetracted "false" @default.
• W4283700944 workType "article" @default.